MedTrace Logo

Living Well on Androgen Deprivation Therapy

NCT02108613 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-07-29

No results posted yet for this study

Summary

Approximately half of men treated for prostate cancer will be offered hormone deprivation therapy during their cancer experience. The secondary effects of this treatment can result in osteoporosis, cardiovascular disease, stroke, diabetes, and diminished sexual health. To promote healthy lifestyle choices for couples and maintain their intimacy and emotional health we propose the Living Well, an innovative program that combines nutrition, physical activity, and sexual health initiatives in one integrated service. This project will be piloted at the Vancouver Island Centre with an expected 100 patients over 1 year. Over a six month period both the experimental and control groups will have access to a workbook (designed for men with prostate cancer and on hormone deprivation therapy) and sexual health counseling. The experimental group will also have access to an exercise and a nutritional program and support by volunteers to keep motivated. Assessment will look at quality of life, physical factors, and biomarkers associated with secondary disease.

Conditions

Interventions

BEHAVIORAL

Exercise Sessions

8 weeks of weekly exercise classes taught by a certified exercise physiologist.

BEHAVIORAL

Nutrition Education

Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.

BEHAVIORAL

Peer Support Volunteer

Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.

Sponsors & Collaborators

  • The Prostate Centre - Vancouver Island and the Gulf Islands

    collaborator UNKNOWN

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Jennifer Goulart, MD · British Columbia Cancer Agency

  • Satnam Sidhu, RD · British Columbia Cancer Agency

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-03-31
Completion
2017-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02108613 on ClinicalTrials.gov